| HUMAN-TRIAL | evidence | Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Semaglutide | Weight & fat loss · human-rct · n = 150 | — |
| HUMAN-TRIAL | evidence | Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. | Semaglutide | Weight & fat loss · human-observational · n = 220 | — |
| HUMAN-TRIAL | evidence | A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Semaglutide | human-rct · n = 512 | — |
| HUMAN-TRIAL | evidence | A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) | Rybelsus | n = 38 | — |
| HUMAN-TRIAL | evidence | Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) | Semaglutide | Weight & fat loss · human-rct · n = 667 | — |
| HUMAN-TRIAL | evidence | Treating PCOS With Semaglutide vs Active Lifestyle Intervention | Rybelsus | Weight & fat loss · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 884 | — |
| HUMAN-TRIAL | evidence | GLP-1 RA for Stage 1 Type 1 Diabetes | Semaglutide | Glycemic control · human-rct · n = 15 | — |
| HUMAN-TRIAL | evidence | Combined Active Treatment in Type 2 Diabetes With NASH | Ozempic | Glycemic control · human-rct · n = 192 | — |
| HUMAN-TRIAL | evidence | Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes | Semaglutide | Glycemic control · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR) | Ozempic | Glycemic control · human-observational · n = 34238 | — |
| HUMAN-TRIAL | evidence | A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight | Semaglutide | Weight & fat loss · human-rct · n = 1200 | — |
| HUMAN-TRIAL | evidence | Semaglutide Therapy for Alcohol Reduction - Tulsa | Semaglutide | Addiction & substance use · human-rct · n = 80 | — |
| HUMAN-TRIAL | evidence | Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | Wegovy | Weight & fat loss · human-observational · n = 125000 | — |
| HUMAN-TRIAL | evidence | Free Fatty Acid Effects In Type 2 Diabetes | Semaglutide | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus | Semaglutide | Glycemic control · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 107 | — |
| HUMAN-TRIAL | evidence | A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese | Semaglutide | Glycemic control · human-rct · n = 32 | — |
| HUMAN-TRIAL | evidence | Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 458 | — |
| HUMAN-TRIAL | evidence | Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity | Semaglutide | Weight & fat loss · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide | Semaglutide | Glycemic control · human-rct · n = 18 | — |
| HUMAN-TRIAL | evidence | DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy | Semaglutide | Glycemic control · human-observational · n = 291 | — |
| HUMAN-TRIAL | evidence | A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects | NN9535 | Glycemic control · human-rct · n = 44 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 581 | — |
| HUMAN-TRIAL | evidence | Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | Semaglutide | Weight & fat loss · human-rct · n = 17604 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) | Semaglutide | Glycemic control · human-observational · n = 333 | — |
| HUMAN-TRIAL | evidence | Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo | Semaglutide | human-rct · n = 30 | — |
| HUMAN-TRIAL | evidence | The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes | Semaglutide | Glycemic control · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) | Rybelsus | human-rct · n = 44 | — |
| HUMAN-TRIAL | evidence | Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct | — |
| HUMAN-TRIAL | evidence | A Study of a Novel Precision Medicine Approach For Obesity | Semaglutide | Weight & fat loss · human-rct · n = 135 | — |
| HUMAN-TRIAL | evidence | A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | Semaglutide | Glycemic control · human-rct · n = 36 | — |
| HUMAN-TRIAL | evidence | Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®. | Ozempic | human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes | Ozempic | human-rct · n = 61 | — |
| HUMAN-TRIAL | evidence | Treatment to Regress to Normoglycemia in Women with a Recent History of GDM | Ozempic | Glycemic control · human-rct · n = 102 | — |
| HUMAN-TRIAL | evidence | Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults | Semaglutide | Weight & fat loss · n = 60 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 155 | — |
| HUMAN-TRIAL | evidence | A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM | Semaglutide | Glycemic control · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 92 | — |
| HUMAN-TRIAL | evidence | IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion | Semaglutide | human-rct · n = 75 | — |
| HUMAN-TRIAL | evidence | The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients | Semaglutide | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | Semaglutide | Lipid & cardiovascular markers · human-rct · n = 7101 | — |
| HUMAN-TRIAL | evidence | A Study of Cardiovascular Events iN Diabetes Plus | Semaglutide | Glycemic control · human-rct · n = 21296 | — |
| HUMAN-TRIAL | evidence | Latino Semaglutide Study | Semaglutide | Weight & fat loss · human-rct · n = 119 | — |
| HUMAN-TRIAL | evidence | Genetics of the Acute Response to Oral Semaglutide | Rybelsus | Glycemic control · n = 1000 | — |
| HUMAN-TRIAL | evidence | Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 | Wegovy | Weight & fat loss · human-rct · n = 20 | — |
| HUMAN-TRIAL | evidence | A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together | Ozempic | Glycemic control · human-rct · n = 30 | — |
| HUMAN-TRIAL | evidence | Semaglutide Use in Acute Pulmonary Embolism | Semaglutide | human-observational · n = 18 | — |
| HUMAN-TRIAL | evidence | A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | Semaglutide | Weight & fat loss · human-rct · n = 80 | — |